Connor Clark & Lunn Investment Management Ltd. trimmed its holdings in HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 38.2% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 30,109 shares of the company's stock after selling 18,615 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.'s holdings in HUTCHMED were worth $434,000 at the end of the most recent reporting period.
Other hedge funds have also bought and sold shares of the company. Point72 Hong Kong Ltd bought a new stake in HUTCHMED in the 3rd quarter worth approximately $421,000. State Street Corp boosted its stake in shares of HUTCHMED by 0.9% in the 3rd quarter. State Street Corp now owns 349,524 shares of the company's stock worth $6,826,000 after buying an additional 3,078 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of HUTCHMED by 362.2% in the third quarter. Jane Street Group LLC now owns 62,997 shares of the company's stock worth $1,305,000 after acquiring an additional 49,366 shares during the period. Public Employees Retirement System of Ohio purchased a new stake in HUTCHMED during the third quarter valued at $35,000. Finally, Crossmark Global Holdings Inc. increased its position in HUTCHMED by 10.7% during the fourth quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company's stock valued at $268,000 after acquiring an additional 1,799 shares during the last quarter. Hedge funds and other institutional investors own 8.82% of the company's stock.
HUTCHMED Stock Down 3.1 %
HCM stock traded down $0.47 during midday trading on Tuesday, reaching $14.62. 44,633 shares of the company's stock traded hands, compared to its average volume of 106,315. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07. HUTCHMED has a 52-week low of $12.84 and a 52-week high of $21.92. The stock's 50-day moving average is $14.69 and its 200 day moving average is $16.46.
Wall Street Analyst Weigh In
Separately, StockNews.com upgraded HUTCHMED from a "hold" rating to a "buy" rating in a research note on Friday.
Read Our Latest Analysis on HUTCHMED
HUTCHMED Profile
(
Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
See Also
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
